Bravo-Soto Gonzalo A, Juri Carlos
Centro evidencia UC, Pontificia Universidad Católica de Chile, Santiago, Chile; Proyecto Epistemonikos, Santiago, Chile. Email:
Proyecto Epistemonikos, Santiago, Chile; Departamento de Neurología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Medwave. 2017 Jun 16;17(Suppl2):e6974. doi: 10.5867/medwave.2017.6974.
It is postulated cannabinoids may have benefits in Parkinson's disease. However, its actual clinical effectiveness is still discussed. To answer this question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We identified six systematic reviews including eight studies overall, of which four were randomized trials relevant for the question of interest. We extracted data from the systematic reviews, reanalyzed data of primary studies included in these reviews, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. We concluded cannabinoids probably do not decrease symptoms in Parkinsons disease or dyskinesia, and probably are associated to frequent adverse effects in patients with Parkinsons disease.
据推测,大麻素可能对帕金森病有益。然而,其实际临床疗效仍存在争议。为回答这一问题,我们使用了Epistemonikos,这是健康领域最大的系统评价数据库,通过筛选包括MEDLINE、EMBASE、Cochrane等在内的多个信息来源进行维护。我们识别出六项系统评价,总共包括八项研究,其中四项为与感兴趣问题相关的随机试验。我们从系统评价中提取数据,重新分析这些评价中纳入的原始研究数据,进行荟萃分析,并使用GRADE方法生成结果总结表。我们得出结论,大麻素可能不会减轻帕金森病或异动症的症状,并且可能与帕金森病患者频繁出现的不良反应有关。